| Bioactivity | JMF4073 is a thymidylate (TMP) and cytidylate (CMP) kinases inhibitor with IC50s of 0.16 μM and 0.17 μM, respectively. JMF4073 eliminates wild-type (WT)-Bcr-Abl-transformed myeloid cells in vitro and in vivo[1]. |
| Invitro | WT-Bcr-Abl 细胞对 JMF4073 高度敏感，GI50 为 0.67 μM，而 T315I-Bcr-Abl-32D 和未转化的 32D 细胞分别为 1.5 μM 和 4.2 μM。这些细胞中的整体酪氨酸磷酸化水平不受 JMF4073 治疗的影响[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> JMF4073 相关抗体: |
| In Vivo | JMF4073（5 mg/kg；腹腔注射；每日；持续 14 天）抑制 WT-Bcr-Abl-32D 携带小鼠的白细胞计数。此外，JMF4073 可延长白血病小鼠的生存期[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1927930-61-7 |
| Formula | C18H22FN3O4S |
| Molar Mass | 395.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chang-Yu Huang, et al. Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK. Commun Biol. 2024 Jul 10;7(1):843. |